The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present retrospective and observational work is to investigate the prognostic value of 18F-fluorocholine (18F-FCH) positron emission tomography (PET) parameters in mCRPC.
Between March 2013 and August 2016, 29 patients with mCRPC were included. They all received three-weekly docetaxel after androgen deprivation therapy, and they underwent 18F-FCH PET/computed tomography (CT) before and after the therapy. Semi-quantitative indices such as maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean) with partial volume effect (PVC-SUV) correction, metabolically active tumour volume (MATV), and total lesion activity (TLA) with partial volume effect (PVC-TLA) correction were measured both in pre-treatment and post-treatment 18F-FCH PET/CT scans for each lesion. Whole-body indices were calculated as sum of values measured for each lesion (SSUVmax, SPVC-SUV, SMATV, and STLA). Progression-free survival (PFS) and overall survival (OS) were considered as clinical endpoints. Univariate and multivariate hazard ratios for whole-body 18F-FCH PET indices were performed, and p < 0.05 was considered as significant.
Cox regression analysis showed a statistically significant correlation between PFS, SMATV, and STLA. No correlations between OS and 18F-FCH PET parameters were defined probably due to the small sample size.
Semi-quantitative indices such as SMATV and STLA at baseline have a prognostic role in patients treated with docetaxel for mCRPC, suggesting a potential role of 18F-FCH PET/CT imaging in clinical decision-making.
Contrast media & molecular imaging. 2019 Mar 26*** epublish ***
E Quaquarini, D D'Ambrosio, F Sottotetti, F Gallivanone, M Hodolic, P Baiardi, R Palumbo, C Vellani, C Canevari, A Bernardo, I Castiglioni, C Porta, G Trifirò
Medical Oncology Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy., Medical Physics Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy., Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Milan 20090, Italy., Nuclear Medicine Research Department, Iason, Graz, Austria., Scientific Direction, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy., Nuclear Medicine Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy., Nuclear Medicine Unit, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy., Translational Oncology Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy.